ArticleOpen veterinary journal2025
Cost-effective suspension adaptation of BHK-21 cells for scalable FMD vaccine production in resource-limited settings.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficient Production of Swine Influenza Virus Using Serum-Free Suspension MDCK Cells for Vaccine Manufacturing.Journal of microbiology and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The foot and mouth disease virus (FMDV) remains a significant threat to livestock health and agricultural economies, particularly in endemic regions such as Egypt. Although suspension cultures of baby hamster kidney (BHK)-21 cells are widely used for FMD vaccine production. Suspension cells play a vital role in biomanufacturing, but their high cost often limits their accessibility. This straightforward method offers an efficient and economical solution for obtaining BHK-adapted suspension cells that are ideal for large-scale cultivation in bioreactors. Aim: We developed a simplified and cost-effective method for adapting BHK-21 cells to suspension culture using a progressive accelerated rolling system, eliminating the need for microcarriers or complex bioreactor systems. The resulting suspension-adapted cells (BHK-S) were assessed for growth kinetics, sterility, postthaw viability, and their ability to support FMDV replication and 146S antigen production. Methods: Conversion of adherent BHK-21 to BHK suspension was performed, followed by investigation of cell counts, cell viability, cell morphology, and growth curve analysis. Results: BHK-S cells demonstrated robust growth with >95% viability and a density of 2 × 10 Conclusion: This streamlined and scalable approach for adapting BHK-21 cells to suspension culture offers a practical and affordable alternative for FMD vaccine production in resource-limited settings, facilitating the transition from bench-to-bioprocessing scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.